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Abstract
A rhodopsin-based homology model of the P2Y14 receptor was inserted into a phospholipid bilayer
and refined by molecular dynamics (MD) simulation. The binding modes of several known agonists,
namely UDP-glucose and its analogues, were proposed using automatic molecular docking combined
with Monte Carlo Multiple Minimum calculations. Compared to other P2Y receptors, the P2Y14
receptor has an atypical binding mode of the nucleobase, ribose and phosphate moieties. The
diphosphate moiety interacts with only one cationic residue, namely Lys171 of EL2, while in other
P2Y receptor subtypes three Arg or Lys residues interact with the phosphate chain. Two other
conserved cationic residues, namely Arg253 (6.55) and Lys277 (7.35) of the P2Y14 receptor together
with two anionic residues (Glu166 and Glu174 located in EL2), are likely involved in interactions
with the distal hexose moiety.
Eight subtypes of P2Y receptors, namely P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, and
P2Y14, have been cloned and characterized.1 All of these are G protein-coupled receptors
(GPCRs) belonging to the rhodopsin family. The P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11 are
Gq-coupled receptors and comprise the P2Y1-like receptor family.2 A second family referred
to as the P2Y12-like family consists of the P2Y12, P2Y13, and P2Y14 receptors that couple via
Gi proteins to the inhibition of adenylate cyclase.2 P2Y receptors are widely distributed
throughout the body and are involved in many physiological processes.3 In particular, the
P2Y14 receptor is likely involved in regulation of neuroimmune functions and is highly
expressed in placenta, stomach, and intestine, and with moderate expression in brain, heart,
lung, and spleen.4
In contrast to other P2Y receptor subtypes, the P2Y14 receptor is not activated by either
nucleotide di- or triphosphates, such as ATP, UTP, or UDP, and dinucleotide.5–7
However, sugar-substituted analogues of UDP, namely UDP-glucose, UDP-galactose, and
UDP-N-acetyl-glucosamine, are naturally occurring agonists of the P2Y14 receptor.4,8,9
Among these ligands, UDP-glucose is the most potent agonist.
Supporting information available: Calculation details including the MD simulation, automatic docking, and MCMM calculation
parameters.
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Recently, molecular models of all known subtypes of P2Y receptors, including the P2Y14
receptor were published, and general configurations of the binding sites were proposed based
on docking studies performed for the P2Y1 and P2Y12 receptors.2 Several amino acid residues
were suggested to be critical for ligand binding at both P2Y1-like and P2Y12-like receptor
families of P2Y receptors.
Concerning the P2Y12-like family three cationic residues, namely Arg3.29, Lys located in EL2,
and Lys7.36 were proposed to be critical for coordination of the phosphate chain of a ligand.
Also, Ser7.43, present in the P2Y1-like family and in the P2Y12 receptor, seems to be involved
in ligand binding via H-bonding with the nucleobase ring. This position is Ala7.43 in the
P2Y13 and P2Y14 receptors. Tyr1.39, which was found to be involved in ligand recognition in
the P2Y1 receptor, is conserved among all P2Y receptors, with the exception of the P2Y11
subtype. Tyr2.53 can interact with the native ligands at P2Y1, 2, 4, 6 subtypes, while in the
P2Y12, 13, 14 receptors the corresponding residue is Met2.53. The P2Y12-like receptors,
especially P2Y13 and P2Y14 receptors, likely have a different configuration of the binding site
or different binding mode of its agonists in comparison to P2Y1-like receptors.2
In this study, a molecular model of the human P2Y14 receptor was refined by insertion into the
phospholipid bilayer followed by 20 ns molecular dynamics simulation, and possible binding
modes of four agonists of the P2Y14 receptor were studied using automatic docking followed
by conformational search analysis.
Homology modeling is one of the most effective methods to study the structure and ligand-
receptor interactions of GPCRs. The models obtained using this approach can provide
information about residue – residue interactions, configuration of the putative ligand binding
site, and possible binding modes of the ligands. However, such models have very similar
configurations of the transmembrane domains (TMs) in comparison to the corresponding TMs
of the template, usually rhodopsin. Homology modeling often cannot provide an accurate
prediction of the configuration of the loops and terminal domains, especially if these sequences
are quite long. Moreover, in most cases homology modeling does not take into account the
natural environment of the membrane-bound GPCRs, although this is an important factor for
the general configuration of a receptor structure and orientation of its sidechains.10
In this study, a previously published rhodopsin-based molecular model of the human P2Y14
receptor2 was refined using 20 ns molecular dynamics (MD) simulation in the phospholipid
bilayer.
The MD simulation was performed using the protocol developed by Woolf and Roux11–14
and applied to MD simulation of the P2Y6 receptor by Costanzi et al.15 This simulation was
run on the Biowulf cluster at the NIH (Bethesda, MD) using CHARMM 32a216 (details given
in Supporting Information). As with the P2Y6 receptor,15 attempts to generate a MD trajectory
without applying nuclear Overhauser enhancement (NOE) restraints led to a loss of the
secondary structure of TM7. For this reason the first 5 ns of the MD were performed with the
NOE restraints applied for the distances between the backbone carbonyl oxygen atom of the
residue n and the backbone NH-group of the residue n+4 of TM7. That constraint preserved
the helical structure of TM7, which remained stable after removing the NOE restraints.
The root mean square deviation (RMSD) of all atoms of the P2Y14 receptor was calculated
from the MD trajectory. As shown in Figure 1 the first plateau of the RMSD was reached after
2.5 ns of MD simulation.
After 5 ns (when the NOE restrains were removed) the value of the RMSD was slightly
increased, and after approximately 8.5 ns of MD simulation the structure of the receptor became
stable. The typical structure of the last 100 ps of the trajectory was considered as a final structure
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of the MD simulation. The Cα-atoms of the transmembrane α-helices of this structure and an
initial structure of the P2Y14 receptor were aligned with RMSD of 3.1 Å (Figure 2).
It was found that in general both structures have very similar configurations of the TMs.
However, the angles along the axes of TM6 and TM7 changed slightly in comparison to the
initial structure. The calculated values of the RMS fluctuations (RMSF) allowed us to indicate
the residues with positions that were most significantly changed during the MD simulation.
Not surprisingly, the highest values of the RMSF corresponded to the residues located in the
extracellular (EL) and intracellular (IL) hydrophilic loops and terminal domains, while the
residues located in the TM domain had the lowest values of the RMSF (Figure 3). In particular,
the greatest change occurred in EL1 and IL3. In addition, during the simulation EL2 was shifted
slightly outward from its initial position. However, the configuration of this longest hydrophilic
loop was not significantly altered during the simulation.
In addition to a conserved disulfide bridge and H bonds involved in formation of the β-sheet,
several additional electrostatic bridges and H bonds were found to form among the residues
located in EL2 (Figure 4).
It was found that additional H bonds can be formed between Arg165(NH, sidechain) –
Glu166(CO, backbone), Lys176(NH, sidechain) – Arg165(CO, backbone), Arg181(NH, sidechain) –
Asn161(CO, backbone). Also, Arg253 (6.55) can interact with Glu174 (EL2), Lys277 (7.35)
interacted with Glu166 (EL2), and Glu12 located in the N-terminal domain appeared near
Arg165 (EL2). These findings suggest that in the case of the P2Y14 receptor, EL2 is a relatively
rigid part of the receptor, and its conformation is constrained through a network of specific
interactions.
The molecular model of the P2Y14 receptor obtained after MD simulation was used for a
molecular docking study of UDP-glucose 1. During the first step, the ligand was docked
automatically to the rigid putative binding site using the Autodock program17 (using
parameters given in Supporting Information). This approach allowed the automatic location
of the most favorable position and conformation of a flexible ligand, while avoiding radical
changes in the receptor structure. The results of the automatic docking were analyzed, and the
3 ligand-receptor complex with the most favorable energy scoring function and most in
agreement with available published data,2,15,18 was selected for further studies. To obtain a
more accurate binding mode of UDP-glucose, the complex obtained after the automatic
docking was used as a starting point for a Monte Carlo Multiple Minimum (MCMM)
conformational search analysis of the ligand inside the putative binding site of the P2Y14
receptor. The MCMM calculations were performed using MacroModel software.19
It should be noted that for four other subtypes of P2Y receptors the Northern (N) conformation
of the ribose ring was proposed as the preferred conformation.20 In the present study
conformers of 1 having both (N)- and (S)-conformations of the ribose ring were examined.
The binding modes of (N)- and (S)-UDP-glucose obtained after MCMM calculations
demonstrated that in both cases the ether oxygen and the 3′-hydroxyl group of the ribose ring
were not involved in H-bonding with the receptor. In contrast, the 2′-hydroxyl group of (N)-
UDP-glucose was H-bonded with the backbone oxygen atom of Asn104 (3.35) (Figure 5),
while the 2′-hydroxyl group of (S)-UDP-glucose formed a H bond with the sidechain amino
group of Asn287 (7.45) and the backbone oxygen atom of Ser284 (7.42).
This means that in the case of (N)-UDP-glucose, the 2′-hydroxyl group could be a H bond
donor, while in case of the (S)-conformation it is more likely to be both donor and acceptor.
The uracil ring of (N)- and (S)-UDP-glucose appeared near and oriented toward Tyr29 (1.39),
which is a highly conserved residue among all P2Y receptors with the exception of Leu1.39
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in the P2Y11 receptor. A similar orientation of the uracil ring was previously proposed for other
subtypes of P2Y receptors.2,14,18 The carbonyl oxygen atom at position 4 of the uracil ring
was located at a distance of 6.5Å from the Tyr29 hydroxyl group. The carbonyl oxygen atom
at position 2 was found at a distance of 4.7Å from the Asn287 sidechain amino group, 6.0Å
from its backbone NH-group, and 5.3Å from the backbone NH-group of Val288. The 3-NH
group of 1 was oriented toward the sidechains of Val32 and Val288. However, the possible
importance of these residues in ligand recognition is yet to be tested experimentally.
In the model, the α-phosphate group of 1 interacted with the hydroxyl groups of Thr280 (7.38)
and Ser284 (7.42). Thr7.38 is conserved among all P2Y receptors with the exception of
Met7.38 of the P2Y11 receptor. Position 7.42 is Ala7.42 in the P2Y1, 2, 4, 6 and P2Y13 receptors,
Met7.42 in the P2Y11 receptor, and Thr7.42 in the P2Y12 receptor.
It was proposed previously2 that the ligand phosphate chain is located among three cationic
residues, namely Arg3.29, Arg6.55, and Arg7.39 for P2Y1, 2, 4, 6, 11 receptors, and Lys from
the EL2, Arg6.55, and Lys7.35 for P2Y12, 13, 14 receptors. The importance of these residues
in P2Y1 and P2Y2 receptors was demonstrated experimentally.2,21 The binding mode of 1
obtained in the present study demonstrated that in the case of the P2Y14 receptor only Lys171
located in EL2 can interact with the phosphate chain of 1. Arg6.55 and Lys7.35 appeared far
from the phosphate groups and were located near the hexose moiety of the ligand. Moreover,
the sidechain amino group of Lys7.35 was located between hydroxyl groups at the 5 and 3
positions of the glucose ring and formed H-bonds with both these groups. Also, the 3-hydroxyl
group interacted with Glu166, while the 5-hydroxyl group seemed to be H-bonded with Glu174
located in EL2. Interestingly, Glu174 of the P2Y14 receptor corresponds to Asp204 of the
P2Y1 receptor located in EL2 at a site two residues after the conserved Cys. It was demonstrated
using molecular modeling22,23 that Asp204 of the P2Y1 receptor is located within 5Å from
the triphosphate chain of ATP. Based on that model and mutagenesis data24 the involvement
of Asp204 in ligand recognition through a water molecule bridge was proposed. An important
role of the corresponding Asp was also suggested in molecular modeling studies performed
for the P2Y2, P2Y4, and P2Y6 receptors.15,18 Moreover, Glu767 of the human Ca2+
receptor25 and Tyr181 of the THR-receptor26 (both also located in EL2 at a site two residues
after the conserved Cys) were shown to be crucial for receptor activation. In the model obtained,
the ether oxygen atom and the 4- and 2-hydroxyl groups of the glucose moiety were not directly
involved in H bonding with the receptor. As shown in Figure 5, the conformation of the hexose
ring obtained automatically after the docking studies is different from the more stable alternate
chair conformation of such rings. It could be proposed that the obtained conformation of the
hexose moiety is stabilized inside the binding site by specific interactions with the receptor,
namely by H-bonds with Arg253 (6.55), Lys277 (7.35), Glu166 (EL2), and Glu174 (EL2).
In order to explain experimentally observed differences in the activity of UDP-glucose 1, UDP-
galactose 2, UDP-glucuronic acid 3, and UDP-N-acetylglucosamine 4 (Table 1), the three latter
ligands were also subjected to MCMM calculations.
For this purpose, the hexose ring of 1 was converted to a galactose or glucuronic acid moiety
directly in the binding site. It allowed a ligand orientation inside the binding site similar to the
orientation obtained for UDP-glucose. MCMM calculations were subsequently performed for
2 – 4 docked inside the P2Y14 receptor.
The general position of the ligands inside the binding site was unchanged during the MCMM
calculations. All ligand-receptor interactions found for the UDP moiety of 1 were also observed
for analogues 2 – 4. In the case of 3 one additional H-bond was found to form between Glu174
and the 4-hydroxyl group of the ligand, while in the case of 2 additional H-bonds between the
hexose moiety and the receptor were not observed. However, the 4-hydroxyl group of 3 and a
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hexose carbonyl oxygen atom of 2 were unfavorably located in proximity to the hydrophobic
sidechain of Ile173 located in EL2.
When the least potent agonist 4 was docked in the P2Y14 receptor, H-bonding was not observed
between the receptor and the acetamide group of the ligand. In contrast, due to the short distance
between the methyl groups of 4 and Met3.36, the sidechain of Met3.36 shifted away from the
ligand. In addition, the methyl group of 4 was found close to the backbone oxygen atom of
Phe3.32.
In conclusion, compared to other P2Y receptors, the P2Y14 receptor has an atypical binding
mode of the nucleobase, ribose and phosphate moieties. The ligand binding modes obtained
in this study demonstrated that two key cationic residues, namely Arg6.55 and Lys7.35,
together with two anionic residues (Glu166 and Glu174 located in EL2), can interact with the
hexose moiety. A third conserved key cationic residue, namely Lys171, interacts with the α-
phosphate group of the ligand. The lower activity of 4 and its receptor docking suggest limited
steric tolerance at the 2 position of the hexose moiety.
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Changes in RMSD of atoms of the P2Y14 receptor during the MD simulation.
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The alignment of the initial structure of the P2Y14 receptor (grey) and the structure obtained
after MD simulation (colored). TMI – blue; TMII – light blue; TMIII – cyan; TMIV – lime
green; TMV – green; TMVI – orange; TMVII – red.
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RMSF of the Cα-atoms of the P2Y14 receptor.
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The residue – residue bridges served to constrain the configuration of the EL2.
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The binding mode of the UDP-glucose with the P2Y14 receptor obtained after MCMM
calculations. Three key cationic residues, namely Lys171, Arg253, and Lys277 are colored in
orange.
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Table 1
Agonist potencies at the human P2Y14 receptor. The experimental values of EC50 for stimulation of PLC (n =
6) were determined in COS-7 cells expressing the receptor (and an engineered G protein for coupling to PLCβ)
were obtained as previously described.8
Ligand R EC50, nM
1, UDP-glucose 354±115
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